| 27.07.2010 |
|
HBM BioVentures Quarterly Report as at 30 June 2010 |
| 13.07.2010 |
|
HBM BioVentures’ largest public investment – Micrus – acquired
by Johnson & Johnson |
| 02.07.2010 |
|
HBM BioVentures sells USD hedging position at a profit |
| 25.06.2010 |
|
Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation |
| 16.06.2010 |
|
Interview with Dr Andreas Wicki, CEO of HBM BioVentures |
| 02.06.2010 |
|
HBM BioVentures: Annual Report Financial year 2009/2010 and invitation to its Shareholders' meeting |
| 02.06.2010 |
|
HBM BioVentures: Invitation to the 9th Ordinary Shareholders' Meeting |
| 02.06.2010 |
|
HBM BioVentures delegates the execution of the share buy-back programme delegated to Bank Sarasin/NZB to avoid interruptions |
| 20.05.2010 |
|
HBM BioVentures hedges some of the currency risks
|
| 03.05.2010 |
|
HBM BioVentures closes successful 2009/2010 financial year with a profit of CHF 66 million
|
| 20.04.2010 |
|
HBM BioVentures is 96% equity-financed after redemption of the convertible bond |
| 12.03.2010 |
|
HBM BioVentures Investor Information |
| 10.02.2010 |
|
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA |
| 29.01.2010 |
|
HBM BioVentures Quarterly Report as at 31 December 2009 |
| 13.01.2010 |
|
ChemoCentryx - an HBM BioVentures portfolio company - receives an option payment of USD 35 million from GlaxoSmithKline for a licensing agreement |
| 04.01.2010 |
|
Major financing round for PTC Therapeutics at 2.2 times the previous valuation |
| 04.01.2010 |
|
HBM BioVentures sells Ziemer Group investment |
